

Tuesday, November 21, 2023

Volume 39 No. 11



NOTICE – Items in this issue will be listed online weekly and printed monthly.

APOLLO MEDICAL HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2023	2022
Total revenues	1,033,625,000	849,955,000
Net Sales	906,430,000	
Cost & expenses	932,296,000	744,790,000
Operating income	88,483,000	91,685,000
Interest income	9,617,000	690,000
Interest expense	10,680,000	5,348,000
Other income (expense), net	1,494,000	(10,866,000)
Net before taxes	88,914,000	76,161,000
Income taxes	30,971,000	26,101,000
Net income	57,943,000	50,060,000
Earnings common share		
Primary	\$1.04	\$1.15
Fully Diluted	\$1.03	\$1.12
Common Shares:		
Full Diluted	46,881,567	45,993,001
Year-end	46,607,356	44,884,522

ARCA BIOPHARMA INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2023	2022
Cost & expenses	3,769,000	6,496,000
Operating income	(3,769,000)	(6,496,000)
Other income (expense), net		(2,000)
Net income	(2,826,000)	(6,419,000)
Earnings common share		
Primary	\$(0.20)	\$(0.45)
Fully Diluted	\$(0.20)	\$(0.45)
Common Shares:		
Full Diluted	14,410,143	14,410,143
Year-end	14,410,143	14,410,143

ARCA BIOPHARMA INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2023	2022
Cost & expenses	5,706,000	9,048,000
Operating income	(5,706,000)	(9,048,000)
Other income (expense), net		(5,000)
Net before taxes	(4,250,000)	
Net income	(4,250,000)	(8,752,000)
Earnings common share		
Primary	\$(0.29)	\$(0.61)
Fully Diluted	\$(0.29)	\$(0.61)
Common Shares:		
Full Diluted	14,410,143	14,410,143
Year-end	14,410,143	14,410,143

ARIDIS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2023	2022
Total revenues	21,146	
Cost & expenses	14,609	24,451
Operating income	6,537	(22,573)
Other income (expense), net	(1,323)	(1,144)
Net before taxes	5,245	
Net income	5,245	(23,984)
Balance for common	5,245	(23,984)
Earnings common share		
Primary	\$0.15	\$(1.35)
Fully Diluted	\$0.11	\$(1.35)
Common Shares:		
Full Diluted	47,179	17,702
Year-end	44,574	17,702

ARTELO BIOSCIENCES INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2023	2022
Cost & expenses	6,690,000	6,811,000
Operating income	(6,690,000)	(6,811,000)
Interest income		2,000
Interest expense		5,000
Other income (expense), net	474,000	70,000
Net before taxes	(6,216,000)	
Net income	(6,216,000)	(6,744,000)
Balance for common	(6,216,000)	
Earnings common share		
Primary	\$(2.15)	\$(2.38)
Fully Diluted	\$(2.15)	\$(2.38)
Common Shares:		
Full Diluted	2,887,000	2,833,000
Year-end	3,162,354	2,855,688

ASCEND WELLNESS HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2023	2022
Total revenues	378,432	293,827
Net Sales	378,432	
Cost & expenses	382,615	297,674
Operating income	(4,183)	(12,908)
Other income (expense), net	25,211	(1,653)
Net before taxes	(7,391)	(36,092)
Income taxes	21,480	29,757
Net income	(28,871)	(65,849)
Earnings common share		
Primary	\$(0.15)	\$(0.36)
Fully Diluted	\$(0.15)	\$(0.36)
Common Shares:		
Full Diluted	196,616	181,833
Year-end	205,935	187,969

ATYR PHARMA INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2023	2022
Total revenues	353	
Cost & expenses	39,313	38,454
Operating income	(38,960)	(38,454)
Other income (expense), net	3,324	634
Net before taxes	(35,636)	
Net income	(35,636)	(37,820)
Earnings common share		
Primary	\$(0.69)	\$(1.34)
Fully Diluted	\$(0.69)	\$(1.34)
Common Shares:		
Full Diluted	51,701	28,185
Year-end	58,560	29,009

AVITA MEDICAL INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2023	2022
Total revenues	35,948,000	24,966,000
Net Sales	35,948,000	
Cost & expenses	66,330,000	46,563,000
Operating income	(30,382,000)	(21,597,000)
Other income (expense), net	2,141,000	307,000
Net before taxes	(28,262,000)	(21,300,000)
Income taxes	54,000	12,000
Net income	(28,316,000)	(21,312,000)
Earnings common share		
Primary	\$(1.12)	\$(0.85)
Fully Diluted	\$(1.12)	\$(0.85)
Common Shares:		
Full Diluted	25,281,920	24,972,331
Year-end	25,550,694	25,030,902

AYTU BIOPHARMA INC

Annual Report

Consolidated Income Statement, Years Ended Jun. 30 (\$):

	2023	2022	2021
Product & service revenue, net	107,399,000	96,669,000	...
Product revenue, net	107,399,000	96,669,000	65,632,000
Cost of sales	40,767,000	44,386,000	36,432,000
Gross profit	66,632,000	52,283,000	29,200,000
Research & development expenses	4,095,000	12,662,000	5,623,000
Selling & marketing expenses	41,448,000	38,713,000	30,308,000
General & administrative expenses	28,630,000	31,167,000	25,500,000
Acquisition related costs	2,919,000
Restructuring costs	4,886,000
Impairment of goodwill	...	65,802,000	...
Impairment expense	5,705,000	9,656,000	12,825,000
Amortization of intangible assets	4,788,000	5,844,000	6,009,000
Gain from contingent consideration	969,000	1,655,000	...
Total operating expenses	83,697,000	162,189,000	88,070,000
Income (loss) from operations	(17,065,000)	(109,906,000)	(58,870,000)
Other income (expense), net	2,050,000
Other gain	...	1,605,000	...
Gain (loss) from contingent consideration	4,459,000
Gain (loss) on extinguishment of debt	...	169,000	(1,569,000)
Gain (loss) on derivative warrant liability	4,793,000
Other Expense/Income - Net	(4,779,000)	(757,000)	...
Total other income (expense)	14,000	1,017,000	840,000
Profit (loss) before income tax	(17,051,000)	(108,889,000)	(58,030,000)
Current state income taxes	46,000	7,000	16,000
Current- Federal	80,000
Total current tax expense	126,000	7,000	16,000
Deferred federal income taxes	...	(91,000)	200,000
Deferred state income taxes	...	(26,000)	43,000
Total deferred tax expense	(126,000)	(117,000)	243,000
Income tax expense (benefit)	...	(110,000)	259,000
Net income (loss)	(17,051,000)	(108,779,000)	(58,289,000)
Weighted average shares outstanding			
- basic	3,339,906	1,469,875	837,334

Fully Diluted	\$(2.55)	\$(2.95)
Common Shares:		
Full Diluted	32,073,448	29,969,435
Year-end	34,241,523	30,213,206

DOMINARI HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	1,034,000	1,034,000
Net Sales	1,034,000	1,034,000
Cost & expenses	16,983,000	11,202,000
Operating income	(15,949,000)	(11,202,000)
Other income (expense), net	42,000	155,000
Gains or losses	(564,000)	(4,390,000)
Net before taxes	(15,966,000)	(14,851,000)
Net income	(15,966,000)	(14,851,000)
Balance for common	(15,966,000)	(18,960,000)

Earnings common share

Primary	\$(3.09)	\$(3.59)
Fully Diluted	\$(3.09)	\$(3.59)
Common Shares:		
Full Diluted	5,159,501	5,283,182
Year-end	5,285,164	5,140,114

EARTH SCIENCE TECHNOLOGIES INC**Earnings, 3 mos. to Jun 30(Consol. - \$):**

	2023	2022
Total revenues	219,934	231,327
Cost & expenses	231,327	692,172
Operating income	(77,090)	(692,172)
Other income (expense), net	547,608	(89,708)
Net before taxes	(89,708)	(154,682)
Net income	(89,708)	(154,682)

Earnings common share

Primary	\$(3.09)	\$(3.59)
Fully Diluted	\$(3.09)	\$(3.59)
Common Shares:		
Year-end	314,881,821	53,851,966

Consolidated Balance Sheet Items, as of (\$):

	2023	2022
Assets:		
Cash & equivalents	91,989	101,807
Inventories	193,796	120,399
Current assets	2,752,719	2,752,719
Net property & equip.	120,399	120,399
Total assets	2,752,719	2,752,719
Liabilities:		
Current liabilities	962,509	204,408
Long-term debt	204,408	1,489,059
Stockholders' equity	1,489,059	(768,713)
Net current assets	(768,713)	(768,713)

EFFECTOR THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Cost & expenses	17,391,000	16,440,000
Operating income	(17,391,000)	(14,429,000)
Interest expense	1,411,000	983,000
Other income (expense), net	(29,000)	11,478,000
Net before taxes	(18,378,000)	(3,846,000)
Net income	(18,378,000)	(3,846,000)
Balance for common	(18,378,000)	(18,378,000)

Earnings common share

Primary	\$(0.41)	\$(0.09)
Fully Diluted	\$(0.41)	\$(0.09)
Common Shares:		
Full Diluted	44,930,987	40,984,273
Year-end	61,465,616	41,152,790

ELECTRONIC SYSTEMS TECHNOLOGY, INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Total revenues	890,295	890,295
Net Sales	890,295	889,035
Cost & expenses	932,732	913,877
Operating income	(42,437)	(24,842)
Interest income	9,183	1,085
Net before taxes	(33,254)	(23,757)
Net income	(33,254)	(23,757)

Earnings common share

Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	4,946,502	4,946,502
Year-end	4,946,502	4,946,502

ELECTRONIC SYSTEMS TECHNOLOGY, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	1,233,016	1,233,016
Net Sales	1,233,016	1,376,195
Cost & expenses	1,326,334	1,329,040
Operating income	(93,318)	47,155
Interest income	17,559	2,459
Net before taxes	(75,759)	49,614
Net income	(75,759)	49,614

Earnings common share

Primary	\$(0.02)	\$0.01
Fully Diluted	\$(0.02)	\$0.01
Common Shares:		
Full Diluted	4,946,502	4,946,502
Year-end	4,946,502	4,946,502

ENDRA LIFE SCIENCES INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Cost & expenses	9,062,955	9,844,178
Operating income	(9,062,955)	(9,844,178)
Other income (expense), net	462,241	(45,318)
Net before taxes	(8,600,714)	(9,889,496)
Income contin. oper.	(8,600,714)	(9,889,496)
Net income	(8,600,714)	(9,889,496)
Balance for common	(8,600,714)	(9,889,496)

Earnings common share

Primary	\$(1.53)	\$(3.60)
Fully Diluted	\$(1.53)	\$(3.60)
Common Shares:		
Full Diluted	5,630,888	2,800,811
Year-end	8,411,777	3,158,723

ESCALON MEDICAL CORP**Annual Report****Consolidated Income Statement, Years Ended Jun. 30 (\$):**

	2023	2022	2021
Product revenue	11,555,907	9,980,343	9,547,606
Licenses & service plans	624,314	722,727	924,011
Revenues, net	12,180,221	10,703,070	10,471,617
Cost of goods sold	6,698,858	6,096,169	6,044,399
Marketing, general & administrative	4,184,051	4,085,982	3,570,433
Research & development	818,769	990,982	890,482
Total costs & expenses	11,701,678	11,173,133	10,505,314
Income (loss) from operations	478,543	(470,063)	(33,697)
Other income	128	506,305	2,530
Interest income	21,845	18,406	21,841
Interest expense	21,845	18,406	21,841
Total other income (expenses), net	(21,717)	488,144	(18,326)
Net income (loss) from continuing operations	456,826
Deferred state income taxes (benefit)	64,399
Change in valuation allowance	(95,065)
Income Taxes - Foreign - Deferred	30,666
Net income	456,826	18,081	(52,023)
Distribution for Preferred Shares	183,695
Net income (loss)	456,826	18,081	(52,023)
Preferred stock dividends	51,600
Undeclared dividends on preferred stocks	...	51,600	51,422
Net income (loss) applicable to common shareholders	221,531	(33,519)	(103,445)
Weighted average shares outstanding - basic	7,415,329	7,415,329	7,415,329
Weighted average shares outstanding - diluted	13,564,202	13,220,202	7,415,329

	2023	2022	2021
Year end shares outstanding	7,415,329	7,415,329	7,415,329
Net income (loss) per share - basic	\$0.03	\$0.00	\$(0.01)
Net income (loss) per share - diluted	\$0.03	\$0.00	\$(0.01)
Number of full time employees	38
Total number of employees	...	41	41
Number of common stockholders	1,267	1,267	1,267

□ As of September 27, 2022; □ As of September 24, 2021

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):

	2023	2022
Cash & cash equivalents	889,674	593,869
Restricted cash	256,293	256,165
Accounts receivable, gross	1,807,599	1,778,099
Allowance for doubtful accounts	153,878	236,349
Accounts receivable, net	1,653,721	1,541,750
Raw materials	882,093	1,010,471
Work in process	85,575	138,182
Finished goods	880,717	805,698
Total inventories	...	1,954,351
Allowance for obsolete inventory	260,396	350,396
Inventory, net	1,587,989	1,603,955
Other current assets	249,790	190,043
Total current assets	4,637,467	4,185,782
Equipment	777,785	771,097
Furniture & fixtures	128,499	128,499
Leasehold improvements	39,048	39,048
Property & equipment, gross	945,332	938,644
Less accumulated depreciation & amortization	...	885,984
Less accumulated depreciation	911,268	...
Property & equipment, net	34,064	52,660
Right-of-use assets	503,647	788,257
Licenses, net	69,986	82,750
Other long term assets	62,787	62,788
Total assets	5,307,951	5,172,237
Line of credit	...	201,575
Current portion of long-term debt	3,105	...
Current portion of note payable	37,087	3,401
Current portion of economic injury disaster (EIDL) loan	...	3,105
Accounts payable	1,205,510	1,012,451
Accrued compensation	...	445,651
Customer deposits	...	212,555
Warranty reserve	...	32,078
Tax payable	...	100,380
Other accruals	651,978	111,332
Related party accrued interest	112,389	112,389
Current portion of operating lease liabilities	329,638	304,737
Deferred revenue	426,227	332,383
Other short term liabilities	...	129,961
Liabilities of discontinued operations	87,125	...
Total current liabilities	2,853,059	3,001,998
Note payable, net of current portion	159,511	3,888
Operating lease liabilities, net of current portion	214,103	538,794
Economic Injury Disaster loan	...	149,540
EIDL loan	146,435	...
Total long-term liabilities	520,049	692,222

Total liabilities	3,373,108	3,694,220
Series A convertible preferred stock	645,000	645,000
Common stock	7,415	7,415
Additional paid-in capital	69,702,043	69,702,043
Retained earnings (accumulated deficit)	(68,419,615)	(68,876,441)
Total shareholders' equity	1,934,843	1,478,017
Total Equity	1,934,843	...

Recent Dividends:**1. Escalon Medical Corp series A preferred.**

No dividends paid.

2. Escalon Medical Corp common.

No dividends paid.

Annual Dividends:**1. Escalon Medical Corp series A preferred.**

No dividends paid.

2. Escalon Medical Corp common.

No dividends paid.

ESCALON MEDICAL CORP**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s 2023 10-K Report: "Opinion on the Financial Statements We have audited the accompanying balance sheet of Escalon Medical Corp. (the "Company") and Subsidiaries as of June 30, 2023, the related consolidated statements of operations, stockholders' equity and cash flows for the year ended June 30, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2023, and the results of its operations and its cash flows for the year ended June 30, 2023, in conformity with accounting principles generally accepted in the United States of America. Explanatory Paragraph - Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company's historical recurring losses from operations and negative cash flows from operating activities raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

FG FINANCIAL GROUP, INC (NEW)**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2023	2022
Total revenues	8,713	(583)
Cost & expenses	8,757	7,400
Operating income	(9,301)	(9,301)
Net before taxes	(9,301)	(9,301)
Income contin. oper.	(9,301)	(9,301)
Net income	(1,573)	(9,301)
Balance for common	(2,464)	(10,195)
Earnings common share		
Primary	\$(0.26)	\$(1.55)
Fully Diluted	\$(0.26)	\$(1.55)
Common Shares:		
Full Diluted	9,564	6,589
Year-end	10,304	9,278

GEN DIGITAL INC**Earnings, 6 mos. to (Consol. - \$000):**

	09/29/23	09/30/22
Total revenues	1,894,000	1,455,000
Cost & expenses	1,385,000	903,000
Operating income	387,000	502,000
Interest expense	343,000	79,000
Other income (expense), net	1,000	(5,000)
Gains or losses	4,000
Foreign currency	2,000	1,000
Net before taxes	63,000	424,000
Income taxes	(275,000)	155,000
Net income	338,000	269,000
Earnings common share		
Primary	\$0.53	\$0.46
Fully Diluted	\$0.52	\$0.45
Common Shares:		
Full Diluted	644,000	599,000
Year-end	641,000	661,000

GEOVAX LABS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Cost & expenses	19,049,189	8,722,589
Operating income	(19,049,189)	(8,641,063)
Interest income	674,835	3,747
Net before taxes	(18,374,354)
Net income	(18,374,354)	(8,637,316)
Balance for common	(18,374,354)
Earnings common share		
Primary	\$(0.69)	\$(0.63)
Fully Diluted	\$(0.69)	\$(0.63)
Common Shares:		
Full Diluted	26,442,847	13,818,315
Year-end	26,695,287	26,334,953

ICC HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Total revenues	40,271,117	30,805,437
Cost & expenses	37,544,069	36,256,184
Operating income	2,727,048	(5,450,747)
Net before taxes	2,727,048	(5,450,747)
Income taxes	562,014	(1,161,840)
Net income	2,165,034	(4,288,907)
Earnings common share		
Primary	\$0.74	\$(1.40)
Fully Diluted	\$0.73	\$(1.40)
Common Shares:		
Full Diluted	2,969,975	3,073,689
Year-end	3,137,228	3,289,558

ISPECIMEN INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Total revenues	4,575,339	4,857,348
Cost & expenses	10,679,584	9,800,743
Operating income	(6,104,245)	(4,943,395)
Interest income	225,144	26,535
Other income (expense), net	(29,255)	6,630
Net before taxes	(5,915,426)
Net income	(5,915,426)	(4,990,551)
Earnings common share		
Primary	\$(0.66)	\$(0.57)
Fully Diluted	\$(0.66)	\$(0.57)
Common Shares:		
Full Diluted	9,011,644	8,793,723
Year-end	9,063,274	8,873,711

ISPECIMEN INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	7,353,090	7,440,760
Cost & expenses	15,651,415	15,485,214
Operating income	(8,298,325)	(8,044,454)
Interest income	292,506	87,347
Other income (expense), net	(9,173)	9,778
Net before taxes	(8,026,527)
Net income	(8,026,527)	(8,086,241)
Earnings common share		
Primary	\$(0.89)	\$(0.92)
Fully Diluted	\$(0.89)	\$(0.92)
Common Shares:		
Full Diluted	9,029,732	8,822,423
Year-end	9,074,044	8,887,571

JASPER THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Cost & expenses	31,774,000	24,741,000
Operating income	(31,774,000)	(24,741,000)
Interest income	2,532,000
Other income (expense), net	(754,000)	6,912,000
Gains or losses	(344,000)	5,218,000
Net before taxes	(30,340,000)
Net income	(30,340,000)	(12,611,000)
Balance for common	(30,340,000)
Earnings common share		
Primary	\$(0.31)	\$(0.35)
Fully Diluted	\$(0.31)	\$(0.35)
Common Shares:		
Full Diluted	98,605,265	36,353,509
Year-end	110,800,413	37,981,317

KINETA INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2023	2022
Total revenues	5,442
Net Sales	5,000
Cost & expenses	16,894	25,229
Operating income	(11,452)	(21,148)
Interest expense	65	219
Other income (expense), net	281	(200)
Gains or losses	(180)
Net before taxes	(11,416)
Net income	(11,416)	(21,589)
Balance for common	(11,445)	(21,589)
Earnings common share		
Primary	\$(1.09)	\$(14.00)
Fully Diluted	\$(1.09)	\$(14.00)
Common Shares:		
Full Diluted	10,505	1,545
Year-end	10,215	1,551

MIDWEST HOLDING INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Total revenues	67,517,000	2,461,000
Cost & expenses	52,677,000	(6,621,000)
Operating income	11,223,000	7,180,000
Net before taxes	11,223,000	7,180,000
Income taxes	5,876,000	2,597,000
Net income	5,347,000	4,583,000
Earnings common share		
Primary	\$(0.01)	\$2.53
Fully Diluted	\$(0.01)	\$2.52
Common Shares:		
Full Diluted	3,855,462	3,749,564
Year-end	3,744,645	3,737,564

MONOPAR THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Cost & expenses	6,919,247	7,627,879
Operating income	(6,919,247)	(7,627,879)
Interest income	330,966	8,579
Net before taxes	(6,588,281)
Net income	(6,588,281)	(7,619,300)
Balance for common	(6,588,281)
Earnings common share		
Primary	\$(0.49)	\$(0.60)
Fully Diluted	\$(0.49)	\$(0.60)
Common Shares:		
Full Diluted	13,551,776	12,664,387
Year-end	14,198,438	12,855,735

NI HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2023	2022
Total revenues	178,532	141,930
Cost & expenses	155,282	166,507
Operating income	(15,917)	(56,444)
Net before taxes	(15,917)	(56,444)
Income taxes	(3,182)	(11,847)
Net income	(12,735)	(44,597)
Earnings common share		
Primary	\$(0.58)	\$(2.06)
Fully Diluted	\$(0.58)	\$(2.06)
Common Shares:		
Full Diluted	21,325	21,376
Year-end	20,886	21,210

NI HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2023	2022
Total revenues	271,281	231,105
Cost & expenses	227,541	251,336
Operating income	(15,789)	(69,687)
Net before taxes	(15,789)	(69,687)
Income taxes	(3,352)	(14,921)
Net income	(12,437)	(54,766)
Earnings common share		
Primary	\$(0.57)	\$(2.53)
Fully Diluted	\$(0.57)	\$(2.53)
Common Shares:		
Full Diluted	21,253	21,360
Year-end	20,576	21,148

NORDICUS PARTNERS CORP**Annual Report****Consolidated Income Statement, Years Ended Mar. 31 (\$):**

	2023	2022	2021 (revised)
General & administrative expenses	39,602
Selling, general & administrative expenses	102,286
Non-cash compensation	8,141,501
Operating expenses	196,500	309,000	326,000
Income (loss) from operations	(8,479,889)	(309,000)	(326,000)
Interest expense	382
Other income - transaction fee	8,055	22,000	...
Interest & other income (expenses)	7,673
Income (loss) from operations before provision for income taxes	(8,472,216)	(287,000)	(326,000)
Net income (loss)	(8,472,216)	(287,000)	(326,000)
Weighted average shares outstanding - basic	5,938,851	944,651	566,773
Weighted average shares outstanding - diluted	5,938,851	944,651	566,773
Year end shares outstanding	8,296,248	5,681,248	565,247
Net income (loss) per common share - basic	\$(1.43)	\$(0.30)	\$(0.58)
Net income (loss) per common share - diluted	\$(1.43)	\$(0.30)	\$(0.58)
Number of part time employees	...	1	1
Number of common stockholders	112	63	318
Foreign currency translation adjustments	665

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-50 stock split, March 11, 2022; ³ Shares increased due to the effect of issuance of common stock for investor; ⁴ Approximately; ⁵ As of June 17, 2022; ⁶ As of September 8, 2021

Consolidated Balance Sheet, Years Ended Mar. 31 (\$):

	2023	2022
Cash	7,149	246,000
Accounts receivable - other	44,481	...
Prepaid expenses & other current assets	770	4,000
Total current assets	52,400	250,000
Website	2,625	...
Total assets	55,025	250,000
Accounts payable & accrued expenses	12,127	43,000
Related party payable	13,886	12,000
Accounts payable and accrued expenses	1,354	...
Total current liabilities	27,367	55,000
Total liabilities	27,367	55,000
Common stock	8,296	6,000
Additional paid-in capital	42,246,688	33,944,000
Retained earnings (accumulated deficit)	(42,197,663)	(33,725,000)
Accumulated other comprehensive income (loss)	665	...
Treasury stock	30,328	30,000
Total stockholders' equity (deficit)	27,658	195,000
Total Equity	27,658	...

Recent Dividends:**1. Nordicus Partners Corp common.**

No dividends paid.

Annual Dividends:**1. Nordicus Partners Corp common.**

No dividends paid.

NORDICUS PARTNERS CORP**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Fruci & Associates II, PLLC, as it appeared in the 2023 10K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of Nordicus Partners Corporation and Subsidiary ("the Company") as of March 31, 2023, and the related consolidated statements of operations, changes in stockholders' equity, and cash flows for the year then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has not generated revenue, incurred losses since inception, and has an accumulated deficit. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

NORDICUS PARTNERS CORP**Earnings, 3 mos. to Jun 30(Consol. - \$):**

	2023	2022
Cost & expenses	51,589	5,035,000
Operating income	(51,589)	(5,035,000)
Interest income	1,913	...
Other income (expense), net	9,380	...
Net before taxes	(40,296)	(5,035,000)
Net income	(40,296)	(5,035,000)
Earnings common share		
Primary	\$(0.89)	...
Fully Diluted	\$(0.89)	...
Common Shares:		
Full Diluted	8,570,973	5,681,248
Year-end	10,796,248	5,681,248

Consolidated Balance Sheet Items, as of (\$):

	2023
Assets:	
Cash & equivalents	32,040
Current assets	32,815
Total assets	1,785,454
Liabilities:	
Current liabilities	23,153
Stockholders' equity	1,762,301
Net current assets	9,662

NOVACCESS GLOBAL INC**Earnings, 9 mos. to Jun 30(Consol. - \$):**

	2023	2022
Cost & expenses	2,056,751	1,074,187
Operating income	(2,056,751)	(1,074,187)
Interest expense	857,742	1,152,731
Other income (expense), net	(42,788)	568,719
Net before taxes	(2,957,281)	...
Net income	(2,957,281)	(1,658,199)
Balance for common	(3,001,522)	(1,658,199)
Earnings common share		
Primary	\$(0.15)	\$(0.11)
Fully Diluted	\$(0.15)	\$(0.11)
Common Shares:		
Full Diluted	20,290,280	16,032,484
Year-end	21,535,457	18,534,090

OCUGEN INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Cost & expenses	56,908,000	60,718,000
Operating income	(56,908,000)	(60,718,000)
Other income (expense), net	3,323,000	1,306,000
Net before taxes	(53,585,000)	(59,412,000)
Net income	(53,585,000)	(59,412,000)

Balance for common (53,585,000) (59,412,000)

Earnings common share

Primary (0.22) (0.28)

Fully Diluted (0.22) (0.28)

Common Shares:

Full Diluted 240,222,667 212,755,746

Year-end 256,499,987 216,688,437

PLUS THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	3,600,000	...
Net Sales	3,600,000	...
Cost & expenses	13,061,000	14,213,000
Operating income	(9,461,000)	(14,140,000)
Interest income	290,000	74,000
Interest expense	333,000	552,000
Other income (expense), net	1,000	...
Gains or losses	(2,000)	...
Net before taxes	(9,506,000)	...
Net income	(9,506,000)	(14,617,000)
Balance for common	(9,506,000)	...
Earnings common share		
Primary	\$(3.54)	\$(9.15)
Fully Diluted	\$(3.54)	\$(9.15)
Common Shares:		
Full Diluted	2,688,232	1,585,946
Year-end	4,522,656	2,171,333

PURE BIOSCIENCE INC**Annual Report****Consolidated Income Statement, Years Ended Jul. 31 (\$):**

	2023	2022	2021
Impairment of tangible assets	315,000
Net product sales	1,871,000	1,813,000	3,698,000
Royalty revenue	6,000	40,000	229,000
Total revenues	1,877,000	1,853,000	3,927,000
Cost of goods sold	906,000	853,000	1,852,000
Gross profit	971,000	1,000,000	2,075,000
Selling, general & administrative	4,302,000	4,106,000	4,047,000
Research & development	297,000	319,000	339,000
Impairment of intangibles	...	299,000	...
Total operating costs & expenses	4,914,000	4,724,000	4,386,000
Income (loss) from operations	(3,943,000)	(3,724,000)	(2,311,000)
Interest expense, net	...	6,000	4,000
Interest income (expense), net	(14,000)
Other income (expense), net	(4,000)	...	(4,000)
Gain on extinguishment of indebtedness, net	...	239,000	...
Total other income (expense)	(18,000)	233,000	(8,000)
Net income (loss) before income taxes	(3,961,000)
Net income (loss)	(3,961,000)	(3,491,000)	(2,319,000)
Weighted average shares outstanding - basic	111,404,418	88,835,424	87,174,312
Weighted average shares outstanding - diluted	111,404,418	88,835,424	87,174,312
Year end shares outstanding	111,856,473 ¹	111,356,473	87,223,141
Net income (loss) per share - basic	\$(0.04)	\$(0.04)	\$(0.03)
Net income (loss) per share - diluted	\$(0.04)	\$(0.04)	\$(0.03)
Number of full time employees	11	15 ²	10 ³
Number of part time employees	1	1 ²	1 ³
Number of common stockholders	219	219 ²	214 ³

¹ Shares increased due to the effect of issuance of common stock in private placements to related parties and issuance of common stock for vested restricted stock units; ² As of October 28, 2022; ³ As of October 28, 2021; ⁴ Approximately

Consolidated Balance Sheet, Years Ended Jul. 31 (\$):		
	2023	2022
Cash & cash equivalents	1,095,000	3,391,000
Accounts receivable, gross	...	201,000
Less allowance for doubtful accounts	...	0
Accounts receivable	285,000	201,000
Raw materials	11,000	19,000
Finished goods	77,000	160,000
Inventories, net	88,000	179,000
Restricted cash	75,000	75,000
Prepaid expenses	61,000	18,000
Total current assets	1,604,000	3,864,000
Computers & equipment	...	1,582,000
Construction in progress	...	78,000
Website	1,615,000	...
Property, plant & equipment, gross	1,615,000	1,660,000
Less: accumulated depreciation	1,394,000	1,040,000
Property, plant & equipment, net	221,000	620,000
Total assets	1,825,000	4,484,000
Accounts payable	422,000	488,000
Accrued liabilities	110,000	87,000
Total current liabilities	532,000	575,000
Total Non-current Liabilities	1,021,000	...
Total liabilities	1,553,000	575,000
Common stock	1,119,000	1,114,000
Additional paid-in capital	132,398,000	132,079,000
Retained earnings (accumulated deficit)	(133,245,000)	(129,284,000)
Total stockholders' equity (deficit)	272,000	3,909,000
Rep Total Equity & Minority Interest	272,000	...

Recent Dividends:

1. PURE Bioscience Inc common.

No dividends paid.

Annual Dividends:

1. PURE Bioscience Inc common.

No dividends paid.

PURE BIOSCIENCE INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Weinberg and Company, P.A., as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements: We have audited the accompanying consolidated balance sheets of Pure Bioscience Inc. (the "Company") and Subsidiaries as of July 31, 2023 and 2022, and the related statements of operations, stockholders' equity, and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of July 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and negative cash flows from operating activities that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

QUALSTAR CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2022	2021	2020 (revised)
Net revenues	9,845	9,164	8,097
Cost of goods sold	6,850	5,997	5,790
Gross profit (loss)	2,995	3,167	2,307
Engineering expenses	336	451	501
Sales & marketing expenses	...	1,476	1,516
General & administrative expenses	1,215	809	1,551
General & administrative expenses	1,352
Total operating expenses	2,903	2,736	3,568
Income (loss) from operations	92	431	(1,261)
Other income (expenses)	(32)	2	7
Income (loss) before income taxes	60	433	(1,254)
Current state provision (benefit) for income taxes	5	3	4
Current provision (benefit) for income taxes	5	3	4
Provision (benefit) for income taxes	5	3	4
Net income (loss)	55	430	(1,258)
Weighted average shares outstanding - basic	1,829	1,934	1,926
Weighted average shares outstanding - diluted	1,829	1,934	1,926
Year end shares outstanding	1,627	1,884	1,950
Net income (loss) per share - basic	\$0.03	\$0.22	\$(0.65)
Net income (loss) per share - diluted	\$0.03	\$0.22	\$(0.65)
Number of common stockholders	23	24	24
Net sales	9,845

Accrued bonuses	108	...
Accrued other payroll & related liabilities	140	...
Accrued payroll & related liabilities	...	188
Deferred service revenue	687	622
Lease liabilities, short term	165	117
Accrued warranty	...	142
Accrued outside commissions	...	26
Total current liabilities	2,071	2,072
Lease liabilities, long term	95	204
Deferred service revenue, long-term	510	447
Other long-term liabilities	27	28
Total long-term liabilities	632	679
Total liabilities	2,703	2,751
Common stock	18,218	18,789
Retained earnings (accumulated deficit)	(12,878)	(12,933)
Total shareholders' equity (deficit)	5,340	5,856
Total Equity	5,340	...

¹ As reported by the Company

Recent Dividends:

1. Qualstar Corp common.

No dividends paid.

Annual Dividends:

1. Qualstar Corp common.

No dividends paid.

QUALSTAR CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	4,070,000	4,273,000
Net Sales	4,070,000	...
Cost & expenses	4,398,000	4,556,000
Operating income	(328,000)	(283,000)
Interest income	4,000	...
Other income (expense), net	...	(67,000)
Gains or losses	26,000	...
Net before taxes	(290,000)	(350,000)
Net income	(290,000)	(350,000)
Earnings common share
Primary	\$(0.18)	\$(0.19)
Fully Diluted	\$(0.18)	\$(0.19)
Common Shares:
Full Diluted	1,603,000	1,884,000
Year-end	1,578,035	1,884,033

QUALSTAR CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	7,212,000	7,019,000
Net Sales	7,212,000	...
Cost & expenses	7,382,000	7,154,000
Operating income	(170,000)	(135,000)
Interest income	24,000	...
Other income (expense), net	...	(84,000)
Gains or losses	41,000	...
Net before taxes	(129,000)	(219,000)
Net income	(129,000)	(219,000)
Earnings common share
Primary	\$(0.08)	\$(0.12)
Fully Diluted	\$(0.08)	\$(0.12)
Common Shares:
Full Diluted	1,594,000	1,875,000
Year-end	1,572,890	1,749,345

REGULUS THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2023	2022
Cost & expenses	22,809	21,307
Operating income	(22,809)	(21,307)
Net before taxes	(21,975)	(21,527)
Income taxes	1	1
Net income	(21,976)	(21,528)
Earnings common share
Primary	\$(1.19)	\$(1.46)

Accumulated other comprehensive income (loss)	(2,219,000)	162,000			
Retained earnings (accumulated deficit)	(101,015,000)	(84,021,000)			
Total stockholders' equity (deficit)	8,353,000	23,325,000			
Total equity (deficit)	8,353,000	...			

Recent Dividends:**1. Staffing 360 Solutions Inc common.**

No dividends paid.

2. Staffing 360 Solutions Inc series A preferred.

No dividends paid.

3. Staffing 360 Solutions Inc series E-1 preferred.

No dividends paid.

4. Staffing 360 Solutions Inc series E preferred.

No dividends paid.

5. Staffing 360 Solutions Inc series C preferred (stated value:**\$1.00).**

No dividends paid.

6. Staffing 360 Solutions Inc series B preferred (stated value:**\$10.00).**

No dividends paid.

7. Staffing 360 Solutions Inc series D preferred (stated**value:\$10,000).**

No dividends paid.

8. Staffing 360 Solutions Inc series A preferred (stated value:**\$10.00).**

No dividends paid.

Annual Dividends:**1. Staffing 360 Solutions Inc common.**

No dividends paid.

2. Staffing 360 Solutions Inc series A preferred.

No dividends paid.

3. Staffing 360 Solutions Inc series E-1 preferred.

No dividends paid.

4. Staffing 360 Solutions Inc series E preferred.

No dividends paid.

5. Staffing 360 Solutions Inc series C preferred (stated value:**\$1.00).**

No dividends paid.

6. Staffing 360 Solutions Inc series B preferred (stated value:**\$10.00).**

No dividends paid.

7. Staffing 360 Solutions Inc series D preferred (stated**value:\$10,000).**

No dividends paid.

8. Staffing 360 Solutions Inc series A preferred (stated value:**\$10.00).**

No dividends paid.

STAFFING 360 SOLUTIONS INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Baker Tilly US, LLP, as it appeared in Co.'s 2022 10K: "Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet of Staffing 360 Solutions, Inc. (the "Company") as of December 31, 2022, the related consolidated statements of operations and comprehensive loss, stockholders' deficit, and cash flows, for the fiscal year ended December 31, 2022, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the fiscal year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America. Ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

STAFFING 360 SOLUTIONS INC

Earnings, 6 mos. to (Consol. - \$):

		07/01/23	07/02/22
Total revenues	125,183,000	108,946,000	
Net Sales	125,183,000		
Cost & expenses	126,717,000	109,287,000	
Operating income	(2,960,000)	(1,694,000)	
Other income (expense), net	174,000	(988,000)	
Net before taxes	(5,687,000)	(4,585,000)	
Income taxes	47,000	3,000	
Net income	(5,734,000)	(4,588,000)	
Balance for common	(5,734,000)	(4,588,000)	
Earnings common share			
Primary	\$(1.66)	\$(2.61)	
Fully Diluted	\$(1.66)	\$(2.61)	
Common Shares:			
Full Diluted	3,453,841	1,759,298	
Year-end	4,811,020	1,762,158	

TEMPEST THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2023	2022
Cost & expenses	21,643	25,706
Operating income	(21,643)	(25,706)
Interest income	712	
Interest expense	1,072	1,186
Net before taxes	(22,003)	
Net income	(22,003)	(26,606)
Balance for common	(22,003)	
Earnings common share		
Primary	\$(1.57)	\$(2.46)
Fully Diluted	\$(1.57)	\$(2.46)
Common Shares:		
Full Diluted	14,059	10,816
Year-end	14,323	10,517

THARIMMUNE INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	6,924,064	5,115,500
Operating income	(6,924,064)	(5,115,500)
Interest income	94,898	
Interest expense	16,151	1,591,244
Net before taxes	(6,845,317)	
Net income	(6,845,317)	(6,706,744)
Balance for common	(6,845,317)	
Earnings common share		
Primary	\$(0.47)	\$(0.60)
Fully Diluted	\$(0.47)	\$(0.60)
Common Shares:		
Full Diluted	14,607,394	11,248,041
Year-end	17,511,839	11,529,861

VERICITY INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2023	2022
Total revenues	89,359	82,243
Cost & expenses	81,841	81,297
Operating income	888	(8,205)
Net before taxes	888	(8,205)
Income taxes	790	(194)
Net income	98	(8,011)
Earnings common share		
Primary	\$0.01	\$(0.54)
Fully Diluted	\$0.01	\$(0.54)
Common Shares:		
Full Diluted	14,875	14,875
Year-end	14,875	14,875

*

MERGENT OTC UNLISTED News Reports 0895-3252 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC UNLISTED Manual and provide periodic updates. Send address changes to MERGENT OTC UNLISTED, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2023 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.